Speech-Language Pathologists in Bosque Farms, NM Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Martha Brown Swinney, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1880 Wasmer Cir, Bosque Farms, NM 87068 Phone: 505-869-2201    Fax: 505-869-8416

Ms. Manuela Helena Moya, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1830 Lillie Dr, Bosque Farms, NM 87068 Phone: 505-730-7706

Ms. Michelle Kathryn Williams-gabaldon, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 630 Barnett Rd, Bosque Farms, NM 87068 Phone: 505-720-2765    Fax: 505-869-3011

Emma Boyd, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 980 Bosque Farms Blvd, Bosque Farms, NM 87068 Phone: 505-554-0052    Fax: 833-303-1343

News Archive

Testing One, Two, Three - Over 75% of people with COVID-19 are asymptomatic

A new study published in the British Medical Journal in April 2020 suggests that the number of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is astonishingly higher than the number of cases reported so far. This could help shape future social distancing measures.

How science centers can engage an older America

Drawing on the SPRY Foundation's "The Longevity Revolution: How Science Centers Can Engage an Older America" conference held in June 2006, the latest issue of Public Policy & Aging Report ( PP&AR ) presents this event's key insights, outcomes, and resources.

Emory researchers awarded NIAID contract to develop better drug against influenza

With the flu killing an average of 20,000 people annually in the United States and posing the larger threat of global pandemics, Emory University's strides in influenza research carry the hope of saving lives here and abroad.

BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA

BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.

Read more Medical News

› Verified 8 days ago